FSHD Molecular Characterization

Launched by NATIONWIDE CHILDREN'S HOSPITAL · Oct 20, 2023

Keywords

ClinConnect Summary

This clinical trial, called the FSHD Molecular Characterization, is focused on studying a condition known as Facio-Scapulo-Humeral Dystrophy (FSHD). The goal of the trial is to better understand the clinical features and genetic makeup of this condition, which affects muscle strength and movement. Researchers are currently looking for participants, including individuals aged 13 and older who have been genetically tested and confirmed to have either FSHD1 or FSHD2.

If you or a family member are considering joining the trial, you should know that participants will undergo assessments, including MRI scans, to help gather important information about the disease. However, people who have difficulty completing an MRI or have other medical or cognitive challenges may not be eligible to participate. This study aims to improve our understanding of FSHD, which could lead to better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 13 years or older
• • Genetically proven FSHD1 or FSHD2 as determined by the investigators
• Exclusion Criteria:
• • Inability to complete an MRI scan (Adults only).
• • Other medical or cognitive issues that, in the opinion of the examiner, preclude accurate functional assessment.